PVCT (Provectus Biopharmaceuticals) Shiller PE Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provectus Biopharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Provectus Biopharmaceuticals  (OTCPK:PVCT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Provectus Biopharmaceuticals Shiller PE Ratio Related Terms


Provectus Biopharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Shiller PE Ratio Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Provectus Biopharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PVCT vs TVRD, DYAI, CLRB: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Shiller PE Ratio falls into.



Provectus Biopharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Provectus Biopharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Provectus Biopharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.0023/333.9520*333.9520
=-0.002

Current CPI (Jun. 2026) = 333.9520.

Provectus Biopharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.040 241.428 -0.055
201612 -0.020 241.432 -0.028
201703 -0.010 243.801 -0.014
201706 -0.010 244.955 -0.014
201709 -0.010 246.819 -0.014
201712 -0.010 246.524 -0.014
201803 -0.010 249.554 -0.013
201806 -0.004 251.989 -0.005
201809 -0.004 252.439 -0.006
201812 -0.006 251.233 -0.008
201903 -0.004 254.202 -0.005
201906 -0.006 256.143 -0.007
201909 -0.005 256.759 -0.006
201912 -0.004 256.974 -0.005
202003 -0.005 258.115 -0.006
202006 -0.004 257.797 -0.005
202009 -0.004 260.280 -0.005
202012 -0.004 260.474 -0.005
202103 -0.004 264.877 -0.005
202106 -0.004 271.696 -0.005
202109 -0.003 274.310 -0.003
202112 -0.003 278.802 -0.004
202203 -0.003 287.504 -0.003
202206 -0.003 296.311 -0.003
202209 -0.002 296.808 -0.002
202212 -0.002 296.797 -0.002
202303 -0.002 301.836 -0.002
202306 -0.002 305.109 -0.002
202309 -0.002 307.789 -0.002
202312 -0.002 306.746 -0.002
202403 -0.001 312.332 -0.001
202406 -0.002 314.175 -0.002
202409 -0.002 315.301 -0.003
202412 -0.006 315.605 -0.006
202503 -0.003 319.799 -0.003
202506 -0.004 322.561 -0.004
202509 -0.003 324.800 -0.003
202512 -0.003 324.054 -0.003
202603 -0.003 330.213 -0.003
202606 -0.002 333.952 -0.002

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Provectus Biopharmaceuticals Business Description

Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.